Nemonoxacin
CAS No. 378746-64-6
Nemonoxacin ( —— )
产品货号. M36615 CAS No. 378746-64-6
Nemonoxacin (TG-873870) 是一种口服有效的强效广谱抗生素。Nemonoxacin 对不同种类的葡萄球菌、链球菌和肠球菌、淋病奈瑟菌和流感嗜血杆菌均具有较好的抑制活性。Nemonoxacin 可用于细菌感染和社区获得性肺炎的研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥3863 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Nemonoxacin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Nemonoxacin (TG-873870) 是一种口服有效的强效广谱抗生素。Nemonoxacin 对不同种类的葡萄球菌、链球菌和肠球菌、淋病奈瑟菌和流感嗜血杆菌均具有较好的抑制活性。Nemonoxacin 可用于细菌感染和社区获得性肺炎的研究。
-
产品描述Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
-
体外实验Nemonoxacin (0-5.51 μM; 24 h) shows good antibacterial activity in vitro.Cell Viability Assay Cell Line:MSSA, MRSA Concentration:0-5.51 μM (0-2048 μg/mL) Incubation Time:24 h Result:Inhibited MSSA and MRSA with MIC90 values of 0.12 and 4 μg/mL.
-
体内实验Nemonoxacin (p.o.; 15 min and 6 h after infection) shows potent and broad-spectrum in vivo activity against both Gram-positive (S. aureus, S. capitis, S. pneumonia and E. faecalis) and Gram-negative (E. coli) isolates.Nemonoxacin (p.o.; 6, 12 and 24 h after infection) shows potent activities towards (2.5, 5, 10, 20 mg/kg) S. pneumonia 0613 (PRSP) and (10, 20, 40, 80 mg/kg) K. pneumonia 0607 infections in mouse pulmonary infection model.Animal Model:CD-1 ICR mice (18-22 g; mouse systemic infection model).Dosage:1.6-4.0 mg/kg (S. aureus and S. capitis infections), 2.4-10.0 mg/kg (S. pneumonia infections), 5.0-22.6 mg/kg (E. faecalis infections), 1.6-10.0 mg/kg (E. coli infections)Administration:Oral administration; 15 min and 6 h after infection Result:Showed the ED50s of 2.08, 2.59 and 2.52 mg/kg to against S. aureus ATCC 29213 (MSSA), S. aureus 0705 (MRSA) and S. capitis 0687 (levofloxacin-resistant MRSC), respectively.Animal Model:CD-1 ICR mice (18-22 g; mouse pulmonary infection model).Dosage:2.5, 5, 10, 20 mg/kg (S. pneumonia 0613 (PRSP)); 10, 20, 40, 80 mg/kg (K. pneumonia 0607)Administration:Oral administration; 6, 12 and 24 h after infection Result:Significantly decreased colony counts in vivo.
-
同义词——
-
通路GPCR/G Protein
-
靶点Antibacterial
-
受体Antibacterial
-
研究领域——
-
适应症——
化学信息
-
CAS Number378746-64-6
-
分子量371.43
-
分子式C20H25N3O4
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 2 mg/mL (5.38 mM; 超声助溶 (<60°C)
-
SMILESO(C)C1=C2N(C=C(C(O)=O)C(=O)C2=CC=C1N3C[C@@H](C)C[C@H](N)C3)C4CC4
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Adam HJ, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother. 2009 Nov;53(11):4915-20. ?
021-51111890
购物车()
sales@molnova.cn

